Hub24 Ltd (ASX: HUB) has reported net platform inflows of a record $18.9 billion for the past financial year, up 20%.

Growing demand for financial advice

The financial services platform provider said total funds under administration sat at $164.3 billion at the end of June, also up 20%, comprised of platform funds under administration of $139.5 billion and portfolio, administration and reporting services funds under administration of $24.8 billion.

The company added:

Hub24 delivered strong growth in Q4 FY26, with Platform funds under administration increasing 9% over the quarter to $139.5 billion as at 30 June 2026 (up 24% on previous corresponding period). This reflected continued momentum in net inflows of $4.2 billion, alongside positive market movements of $7.5 billion. In the context of market volatility and the recent tax changes proposed in the Federal Budget, the net inflows were stable on the previous corresponding period when excluding large migrations, with year-on-year growth in superannuation net inflows offset by lower net inflows into Investor Directed Portfolio Services.

Hub24 said during the past quarter, the total number of advisers using its platform increased by 100 to 5,649.

The company said in the most recent data collected by industry analyst Plan For Life, it ranked first in both quarterly and annual net inflows for a 10th consecutive quarter.

Hub24 added:

Hub24 also achieved the largest annual market share gain of all platform providers, increasing market share to 9.9% as at 31 March 2026 (up from 8.6% in the previous corresponding period), and is ranked the sixth largest platform by fund under administration.

The company said strong demand for financial advice was underpinned by demographic trends and Australia’s compulsory superannuation system.

The company added:

The proposed tax changes announced in the Federal Budget further reinforce the need for professional advice and the attractiveness of the superannuation system. With these structural growth drivers and a strong pipeline of opportunities across new and existing relationships, Hub24 is well positioned to deliver ongoing growth.

Broker says shares are looking cheap

Morgan Stanley has included Hub24 in its small-mid cap ideas list, saying in a note to clients that a broader sell-off in Australian technology growth stocks has pushed its share price lower.

Morgan Stanley says Hub24 has “delivered industry leading net flows and funds under administration growth as well as operating leverage in recent periods, yet has underperformed its closest peers”, which are Netwealth Ltd (ASX: NWL), Praemium Ltd (ASX: PPS), and AMP Ltd (ASX: AMP) on a year-to-date basis.

The broker said they believed the Federal Budget created more demand for financial advice and increased relative tax advantages for superannuation, which would benefit Hub24.

Morgan Stanley has a price target of $120 on Hub24 shares compared to $83.97 currently.

The post This ASX financial services company has just reported a 20% jump in funds under management appeared first on The Motley Fool Australia.

More reading

• HUB24 earnings: Record $18.9bn net inflows lift FUA
• 4 ASX share tips from 4 brokers, for returns better than 40%
• Where to invest $10,000 in ASX 200 shares in July
• The superannuation concessional contributions cap just rose to $32,500. Here’s how to make the most of it
• New parents are now earning superannuation on parental leave. Here’s how to make the most of it

Motley Fool contributor Cameron England has positions in Hub24. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24, Netwealth Group, and Praemium. The Motley Fool Australia has positions in and has recommended Netwealth Group. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are charging higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $15.10. In early morning trade on Tuesday, shares are changing hands for $15.48 apiece, up 2.5%.

For some context, the ASX 200 is down 0.6% at this same time.

Telix shares have been on fire since plumbing a one-year closing low of $8.63 on 16 February. Indeed, with today’s intraday lift factored in, the ASX 200 healthcare share has surged 79.4% since that low.

Here’s what’s catching investor interest today.

Telix shares jump on revenue growth

Telix shares are outperforming following the release of the company’s second-quarter results (Q2 2026), covering the six months to 30 June.

Highlights included a 21% year-on-year revenue boost to US$247 million (AU$353 million). Second-quarter revenue was up 7% from the prior quarter.

The company’s Precision Medicine segment brought in US$202 million of that quarterly revenue, a 30% increase from Q2 2025 and up 9% from last quarter.

The quarter also saw Telix finalise its strategic collaboration with antibody discovery and development platform developer Regeneron. The two companies will now work to jointly develop and commercialise next-generation radiopharmaceutical therapies.

Looking at what could impact Telix shares in the months ahead, the company forecasts that full-year 2026 revenue and other income will exceed US$1 billion. Revenue was reported to be tracking in line with the upper end of Telix’s 2026 guidance of US$950 million to US$970 million, plus US$40 million non-refundable other income from Regeneron.

On the expenditure side, Telix increased its full-year 2026 R&D expenditure guidance to US$230 million to US$270 million. The company said the increased spend will support the advancement of high-value clinical programs beyond its original R&D forecast.

What did management say?

Commenting on the results helping boost Telix shares today, CEO Christian Behrenbruch said, “We delivered another quarter of growth with US dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA7 imaging portfolio.”

Behrenbruch added:

This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses.

Looking ahead, Behrenbruch concluded:

We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.

The post Up 79% since February, why are Telix shares jumping higher again on Tuesday? appeared first on The Motley Fool Australia.

More reading

• Top 3 ASX healthcare stocks to watch
• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• These are the 10 most shorted ASX shares
• Down 9%: Is the rebound over for Telix shares?
• These are the 10 most shorted ASX shares

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The WAM Income Maximiser Ltd (ASX: WMX) share price is in focus after the company announced a fully franked monthly dividend of 0.66 cents per share, payable at the end of October 2026.

What did WAM Income Maximiser report?

• Dividend of 0.66 cents per share, fully franked
• Record date: 20 October 2026
• Ex-dividend date: 19 October 2026
• Payment date: 30 October 2026
• Dividend covers the October 2026 period
• Dividend Reinvestment Plan (DRP) available, no discount applied

What else do investors need to know?

WAM Income Maximiser continues its established pattern of delivering monthly, fully franked dividends with this latest announcement. The dividend is set at 0.66 cents per share, in line with recent payments, offering ongoing income to shareholders.

Investors can choose to reinvest their dividends via the company’s Dividend Reinvestment Plan (DRP). The DRP will operate at no discount, with the reinvestment price based on the volume weighted average market price across the four trading days from the ex-dividend date.

It’s important to note that shareholders need to confirm their DRP participation by 5pm on Thursday, 22 October 2026, if they wish to reinvest their dividends.

What’s next for WAM Income Maximiser?

WAM Income Maximiser remains focused on delivering regular, tax-effective income to shareholders through monthly, fully franked dividends. The ongoing DRP provides flexibility for investors seeking to accumulate more shares.

Looking ahead, the company will likely maintain its dividend strategy while monitoring market conditions and the performance of its investment portfolio.

WAM Income Maximiser share price snapshot

Over the past 12 months, WAM Income Maximiser shares have risen 4%, outperforming the S&P/ASX All Ords Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post WAM Income Maximiser announces fully franked October 2026 dividend appeared first on The Motley Fool Australia.

More reading

• Andean Silver Bonanza silver-gold unearthed at Cerro Bayo’s Juanita prospect
• Ophir High Conviction Fund announces FY26 unfranked distribution
• 5 ASX All Ords shares that ripped 200% to 400% in FY26

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.